I know everyone is optimistic about the future of neu, including me. But recently, I have done some more in-depth research on the past of neu. It seems that neu has failed in tbi and Glypromate has also failed. So what is the possibility that nnz-2591 can replicate the positive results in phase 3 clinical trials? Since it is the jewel in the crown, why didn't they develop nnz2591 first, but first developed Trofinetide？
Ann: Neuren initiates development of NNZ-2591 to treat HIE, page-66
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$17.67 |
Change
0.660(3.88%) |
Mkt cap ! $2.270B | |||
| Open | High | Low | Value | Volume |
| $17.48 | $18.44 | $17.48 | $10.18M | 567.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 36 | $17.67 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.68 | 81 | 2 |
View Market Depth
| Last trade - 12.30pm 07/08/2025 (20 minute delay) ? |
| NEU (ASX) Chart |